ABBV
$219.76
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Recent News
AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock
AbbVie Inc. (NYSE:ABBV) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026. AbbVie Inc. (NYSE:ABBV) is a constant part of the 13F portfolio of Fisher Asset Management since the start of 2013. Even though the fund trimmed this stake substantially around 2020, it has started buying shares of the company again since […]
Big drugmakers must face US overcharge claims on medications for low-income patients
By Jonathan Stempel March 17 (Reuters) - A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds
AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
AbbVie slips below its 50-day SMA, signaling short-term weakness, but strong drug growth and a solid long-term uptrend may keep investors holding or buying dips
William Blair Asserts AbbVie Inc. (ABBV) Growth Prospects on Obesity Treatment Opportunities
AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs top healthcare stocks. On March 9, William Blair reiterated an Outperform rating on AbbVie Inc. (NYSE:ABBV). The research firm remains confident about the company’s prospects following positive clinical trial results on a crucial obesity treatment. The company announced top-line results from the Phase 1 multiple-ascending-dose study of […]
AbbVie’s Skin Quality Index Aims To Shape Aesthetics Growth Narrative
Allergan Aesthetics, an AbbVie company, has launched the Skin Quality Index, a standardized framework for assessing skin quality in aesthetics. The new index is intended to give patients and providers clearer language for discussing skin concerns and treatment goals. The initiative focuses on aligning expectations and supporting more consistent treatment planning across Allergan Aesthetics’ portfolio. For investors watching NYSE:ABBV, this move sits alongside a share price of $219.68 and a...